Human Vaccines Market Revenue Will Reach $56.38bn In 2019, According to a New Study on ASDReports

Tuesday 14 April 2015, Amsterdam

A new report, now available on ASDReports, forecasts overall human vaccines revenue will reach $56.38bn worldwide in 2019. That medical industry generated $31.94bn in 2014, according to research in World Vaccines Industry and Market 2015-2025, published in February 2015.

That analysis assesses – through qualitative and quantitative methods – where the vaccines industry heads. That study shows what sales that market and its companies can achieve from 2015, also explaining forces influencing development, production and selling of those pharmaceuticals. Its purpose is to help planners, leaders and investors.

Giving multilevel revenue forecasting, the report's updated investigation predicts sales of human vaccines will multiply from 2015 to 2025. Gains will occur at overall world, submarket, product and national level. Aging populations with higher needs and expectations for healthcare, along with advances in vaccine manufacturing technology and diagnostics, will increase sales of those medicines. That industry’s research and development holds much promise. Emerging countries, such as India and China, are developing a better quality of life. This in turn leads to a desire for better healthcare and government drives to match this. All of that progress gives many commercial opportunities for human vaccines from 2015-2025, predicts the study.

Vaccines form an increasingly attractive segment of the pharmaceuticals industry. They are no longer purely prophylactic. Instead the therapeutic ability of some agents to treat chronic diseases such as HIV/AIDS and cancer will provide new market opportunities. This has since seen a trend where companies are increasingly focusing on the therapeutic side of that business.

Bochung Lam, a healthcare industry analyst, said: “There remains a large market for human vaccines that can not only prevent diseases, but also treat them. Human vaccines are one of the most rapidly expanding sectors in medical treatment. In recent years – and also from 2015 – attention from drug manufacturers, doctors and patients shifts to that progressing and lucrative market.

“Our study notes rising demand for human vaccines, especially to counter pandemics and chronic diseases. The number of patients suffering from those conditions will increase from 2015 to 2025, owing to ageing populations and changing lifestyles. Many of these disorders have no definitive form of treatment, with sufferers so far going largely untreated. Vaccines offer a solution there, and the report expects their demand to increase rapidly during our 10-year revenue forecasts.

“Our research and analyses show regulations and other governmental demands will form a challenge to vaccine developers, manufacturers and marketers from 2015 to 2025. Also forces favouring that market include increased rate of uptake from organisations, giving a widening of vaccine sales to private and public sector customers. Technological advances are leading to innovative formulations, methods of vaccination and ways of storing those agents. This will help to cut costs and bring health benefits to a larger number of people. The new report believes this rapidly developing pharmaceutical sector will continue to grow to 2025. Overall the future looks promising for vaccine development, use and sales.

The new report shows revenue forecasts to 2025 at overall world market, submarket, product and national level. It forecasts sales of these world-level submarkets:

•     Paediatric vaccines
•     Adult Vaccines.

That investigation also forecasts revenues to 2025 for 21 products marketed and expected, including Prevnar-13, Gardasil and PENTAct-HIB. Research, data and analyses cover activities of Merck & Co., Pfizer, Sanofi, GlaxoSmithKline and other companies developing, manufacturing and selling vaccines.

The updated study also discusses R&D and commercial news, shows opinions on the future and predicts revenues to 2025 in 11 leading national markets. That work analyses the United States (US), European Union (Germany, France, Italy, Spain and the UK – the EU5 group), Japan, the BRIC countries (Brazil, Russia, India and China). The survey includes qualitative discussions and projections, including interviews with companies in that industry.